Intrapartum magnesium sulfate and need for intensive delivery room resuscitation

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 100, Issue 1, 2015, Pages F59-F65

  Weisz, Dany E ^a   Shivananda, Sandesh ^b   Asztalos, Elizabeth ^a,c   Yee, Wendy ^d   Synnes, Anne ^e   Lee, Shoo K ^f   Shah, Prakesh S ^c,f  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCMASTER CHILDREN S HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CORTICOSTEROID; MAGNESIUM SULFATE; BRONCHODILATING AGENT; NEUROPROTECTIVE AGENT;

APGAR SCORE; ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHORIOAMNIONITIS; COHORT ANALYSIS; COMPRESSION; CONTROLLED STUDY; DELIVERY ROOM; DRUG INDICATION; FEMALE; GENDER; GESTATIONAL AGE; HUMAN; INFANT MORTALITY; INTRAPARTUM CARE; INTUBATION; MAJOR CLINICAL STUDY; MALE; MATERNAL HYPERTENSION; NEUROPROTECTION; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREMATURITY; RESUSCITATION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; TOCOLYSIS; HEART MASSAGE; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; DELIVERY ROOMS; EPINEPHRINE; FEMALE; GESTATIONAL AGE; HEART MASSAGE; HUMANS; INFANT, NEWBORN; MAGNESIUM SULFATE; MALE; NEUROPROTECTIVE AGENTS; RESPIRATION, ARTIFICIAL; RESUSCITATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84919933451     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2013-305884     Document Type: Article

References (37)

1. Magee L, Sawchuck D, Synnes A, et al. SOGC Clinical Practice Guideline: magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2011;33:516-29.
2. American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010;115:669-71.
3. Royal College of Obstetricians and Gynaecologists. Magnesium sulphate to prevent cerebral palsy following preterm birth: Scientifi c impact paper no. 29. 2011. http:// www.rcog.org.uk/files/rcog-corp/uploaded-files/SIP-No-29.pdf (accessed Dec 2013).
4. Marret S, Marpeau L, Zupan-Simunek V, et al . Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007;114:310-18.
5. Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669-76.
6. Mittendorf R, Dambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:1111-18.
7. Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895-905.
8. Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007;114:289-99.
9. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (1):CD004661.
10. Costantine MM, Weiner SJ. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 2009;114:354-64.
11. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009;200:595-609.
12. Abbassi-Ghanavati M, Alexander JM, McIntire DD, et al. Neonatal effects of magnesium sulfate given to the mother. Am J Perinatol 2012;29:795-800.
13. Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin Perinatol 2001;25:236-47.
14. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999;83:302-20.
15. Ali A, Walentik C, Mantych GJ, et al. Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports. Pediatrics 2003;112:e70-2.
16. Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971;47:501-9.
17. Lipsitz PJ, English IC. Hypermagnesemia in the newborn infant. Pediatrics 1967;40:856-62.
18. Johnson LH, Mapp DC, Rouse DJ, et al. Association of cord blood magnesium concentration and neonatal resuscitation. J Pediatr 2012;160:573-7.
19. Davis DJ, Barrington KJ. Recommendations for neonatal surfactant therapy. Paediatr Child Health 2005;10:109-16.
20. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;358:700-8.
21. Finer NN, Carlo WA, Walsh MC, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970-9.
22. Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012;367:2495-504.
23. Dunn MS, Jefferies AL. Recommendations for neonatal surfactant therapy -addendum. Paediatr Child Health 2012;17:137-8.
24. Basu SK, Chickajajur V, Lopez V, et al. Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection. J Perinat Med 2012;40:185-9.
25. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics 2000;106:1070-9.
26. Canadian Neonatal Network Abstractor's Manual v2.0.0 Toronto: CNN; 2012.http://www.canadianneonatalnetwork.org (accessed Jan 2013).
27. Canadian Neonatal Resuscitation Program Steering Committee. Addendum to the 2006 NRP Provider Textbook: Recommendations for specific modifi cations in the Canadian context. 2010. http://www.cps.ca/images/nrp/NRP-Addendum.pdf (Accessed Dec 2013).
28. Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34.
29. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-9.
30. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1-7.
31. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
32. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364-75.
33. Shah PS, Lee SK, Yoon W, et al. The Canadian Neonatal Network Annual Report 2011. Canadian Neonatal Network, 2012. http://www.canadianneonatalnetwork. org (accessed Jan 2013).
34. Shah PS, Lee SK, Yoon EW, et al. The Canadian Neonatal Network Annual Report 2012. Canadian Neonatal Network, 2013. http://www.canadianneonatalnetwork. org (accessed Dec 2013).
35. Vermont Oxford Network of Very Low Birth Weight Infants. Burlington, VT: Vermont Oxford Network, 2013. [Data accessed from Nightingale Internet Reporting System on 17 December 2013].
36. Pryde PG, Mittendorf R. Using prophylactic, but not tocolytic, magnesium sulfate to reduce cerebral palsy related to prematurity: what dose, and what about infant mortality? J Perinat Med 2011;39:375-8.
37. Mag-CP study. https://www.cpn-rpc.org/MAGCP/home.aspx (accessed Mar 2013).